Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting
at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in
subjects with unresectable and/or metastatic hepatocellular carcinoma.